Copertina

Therapy Sequencing in Relapsed/Refractory MCL

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autore principale:	Eva Giné
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation
di: Nathalie Javidi‐Sharifi, et al.
Pubblicazione: (2025)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
di: Inna Y. Gong, et al.
Pubblicazione: (2026)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
di: Giacomo Loseto, et al.
Pubblicazione: (2025)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
di: Jinyan Xiao, et al.
Pubblicazione: (2025)

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
di: Michèle Hoffmann, et al.
Pubblicazione: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
di: J.T. Jutzi, et al.
Pubblicazione: (2025)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
di: Meirav Kedmi, et al.
Pubblicazione: (2024)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
di: Pier Luigi Zinzani, et al.
Pubblicazione: (2025)

523 | CORRELATION OF BASELINE PET/CT IMAGING AND MOLECULAR FEATURES WITH CLINICAL OUTCOMES IN A POPULATION‐BASED MCL STUDY
di: A. I. Perez‐Valencia, et al.
Pubblicazione: (2025)

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
di: Fenghua Gao, et al.
Pubblicazione: (2025)

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
di: Calogero Vetro, et al.
Pubblicazione: (2026)

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi‐Omic Analysis
di: Juan Quarroz Braghini, et al.
Pubblicazione: (2025)

137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIAL
di: M. Khouja, et al.
Pubblicazione: (2025)

265 | IMPACT OF IGHV REPERTOIRE AFTER IBRUTINIB‐CONTAINING REGIMENS IN YOUNGER UNTREATED MCL PATIENTS: AN ANALYSIS OF THE TRIANGLE DATA EMBEDDED IN THE MULTIPLY PROJECT
di: S. Ragaini, et al.
Pubblicazione: (2025)

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
di: Yoshikazu Ikoma, et al.
Pubblicazione: (2025)

619 | IMPACT OF ASCT CONSOLIDATION AND RITUXIMAB MAINTENANCE ON SURVIVAL IN REAL‐WORLD PATIENTS WITH MANTLE CELL LYMPHOMA IN SPAIN. THE GELTAMO‐MCL‐2022 STUDY
di: A. Marin‐Niebla, et al.
Pubblicazione: (2025)

151 | CLINICAL VALIDITY OF NONINVASIVE GENOTYPING OF MCL AT DIAGNOSIS FROM BLOOD PLASMA BY CIRCULATING TUMOR DNA PROFILING
di: B. Tessoulin, et al.
Pubblicazione: (2025)

Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow‐Up of a Multicenter, Retrospective Real‐World Experience With 321 Cases Outside of Controlled Clinical Trials
Pubblicazione: (2025)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
di: Tengfei Shi, et al.
Pubblicazione: (2025)

615 | IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL‐LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY
di: F. M. Quaglia, et al.
Pubblicazione: (2025)

45 | MULTI‐TARGETED THERAPY WITH ViPOR IN MANTLE CELL LYMPHOMA (MCL); UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE (MRD)
di: C. Melani, et al.
Pubblicazione: (2025)

429 | LOSS OF ENHANCER‐DERIVED lncRNA ZMIZ1‐AS1 INCREASES THE SENSITIVITY TO BCL2‐INHIBITOR VENETOCLAX IN MCL IN VITRO MODELS
di: F. Guidetti, et al.
Pubblicazione: (2025)

273 | REAL‐WORLD OUTCOMES OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A MULTICENTER ANALYSIS WITH A CONTROL COHORT FROM THE EUROPEAN MCL REGISTRY
di: E. Aydilek, et al.
Pubblicazione: (2025)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
di: Francesca Maria Quaglia, et al.
Pubblicazione: (2026)

134 | EFFICACY AND SAFETY OF FIRST‐LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY
di: M. Wang, et al.
Pubblicazione: (2025)

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study
di: Iuliana Vaxman, et al.
Pubblicazione: (2026)

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation
di: Francesco Autore, et al.
Pubblicazione: (2025)

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
di: Enrica Antonia Martino, et al.
Pubblicazione: (2025)

Thioguanine Therapy in Essential Thrombocytosis and Polycythemia Vera
di: J. Janssen, et al.
Pubblicazione: (2025)

Identifying Clones in Myelodysplastic Syndromes by Using Single‐Cell RNA Sequencing
di: Roy Pollak, et al.
Pubblicazione: (2026)

CEBPA ‐bZIP Mutations in AML Patients Treated With Non‐Intensive Therapy: A Study by the Spanish PETHEMA Registry
di: Esther Prados de la Torre, et al.
Pubblicazione: (2026)

Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma
di: Zhiqiang Song, et al.
Pubblicazione: (2026)

267 | EVALUATION OF ESTABLISHED PROGNOSTIC MARKERS IN YOUNGER MANTLE CELL LYMPHOMA PATIENTS UNDER IBRUTINIB CONTAINING REGIMENS—AN ANALYSIS EMBEDDED IN THE MULTIPLY PROJECT
di: K. Gutmair, et al.
Pubblicazione: (2025)

132 | CLINICAL IMPACT OF CLONAL AND SUBCLONAL DRIVER ALTERATIONS IN MANTLE CELL LYMPHOMA SUBTYPES
di: C. López, et al.
Pubblicazione: (2025)

Evaluation of Delayed Initiation of Lenalidomide Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
di: Koji Kawamura, et al.
Pubblicazione: (2025)

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
di: E. Silkenstedt, et al.
Pubblicazione: (2025)

Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
di: Hazim S. Ababneh, et al.
Pubblicazione: (2024)

PET2‐Adapted Therapy in Patients With Advanced‐Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater
di: Antonio Pinto, et al.
Pubblicazione: (2024)

203 | CHARACTERIZATION AND CLINICAL IMPACT OF THE CIRCULATING IMMUNE CELL PROFILE IN PATIENTS WITH FOLLICULAR LYMPHOMA
di: A. Rivero, et al.
Pubblicazione: (2025)

595 | HISTOLOGICAL TRANSFORMATION IN MARGINAL ZONE LYMPHOMA (MALT, NODAL AND SPLENIC): RISK, CLINICAL FEATURES AND OUTCOME
di: J. G. Correa, et al.
Pubblicazione: (2025)